Lilly’s Foundayo earns non-inferiority and cardiometabolic gains in ACHIEVE-4, fueling FDA submission
TL;DR
In ACHIEVE-4, the largest/longest Phase 3 trial of Foundayo (orforglipron) vs insulin glargine in adults with type 2 diabetes at high CV risk, Foundayo met non-inferiority for MACE-4 and showed 16% lower risk for MACE-4 and 23% lower risk for MACE-3; a pre-planned analysis also showed 57% lower risk of all-cause death. The study (2,700+ participants across 15 countries) demonstrated sustained A1C and body-weight improvements through 104 weeks. Lilly intends to submit Foundayo to the FDA for type 2 diabetes by end of Q2.
Topics:businesshealthcare#achieve-4#cardiovascular-safety#foundayo#healthcare#orforglipron#type-2-diabetes
- ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health Eli Lilly
- Lilly's obesity pill helps reduce cardiovascular risks in late-stage trial CNBC
- Americans want weight-loss pills for cost and convenience Reuters
- FDA tells Eli Lilly to round up more safety info on key obesity launch Foundayo Fierce Pharma
- Lilly’s Foundayo Obesity Pill Matches Insulin in Heart Study Bloomberg
Want the full story? Read the original reporting
Read on Eli Lilly